PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT3004456

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
LUNG-HUANG KUO	08/22/2014
HSIAO-PING FANG	08/26/2014
MING-FENG WU	08/22/2014
YU-SHENG CHANG	08/22/2014

RECEIVING PARTY DATA

Name:	SCINOPHARM TAIWAN, LTD.
Street Address:	NO. 1, NAN-KE 8TH ROAD
Internal Address:	SOUTHERN TAIWAN SCIENCE PARK
City:	SHAN-HUA, TAINAN
State/Country:	CHINA
Postal Code:	74144

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14315642

CORRESPONDENCE DATA

Fax Number: (415)576-0300

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (925) 472-5000

Email: kheldt@kilpatricktownsend.com **Correspondent Name:** WILLIAM B. KEZER, ESQ.

Address Line 1: KILPATRICK TOWNSEND & STOCKTON LLP TWO EMBARCADERO CENTER, 8TH FLOOR Address Line 2: Address Line 4: SAN FRANCISCO, CALIFORNIA 94111-3823

ATTORNEY DOCKET NUMBER: 65322-908921 (001910US)	
NAME OF SUBMITTER:	KIMBERLY HELDT
SIGNATURE:	/Kimberly Heldt/
DATE SIGNED:	09/01/2014

Total Attachments: 3

502957858

source=Executed Assignment abiraterone#page1.tif

PATENT REEL: 033646 FRAME: 0234 source=Executed_Assignment_abiraterone#page2.tif source=Executed_Assignment_abiraterone#page3.tif

PATENT REEL: 033646 FRAME: 0235

ASSIGNMENT

(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

"PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF,"

filed with the U.S. Patent & Trademark Office on June 26, 2014

and assigned serial no. 14/315,642.

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

- Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Scinopharm Taiwan, Ltd., a limited company having a principal place of business at No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, 74144, Taiwan ("Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

PATENT REEL: 033646 FRAME: 0236 ASSIGNMENT U.S. Serial No. 14/315,642 Attorney Docket No. 65322-908921 (001910US) Page 2 of 3

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
- 2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
- 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
- 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
- Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
- Authorize Kilpatrick Townsend & Stockton to insert above the application number and filing date of the above-described patent application when known.

Signed on the dates indicated beside our [my] signatures (signature).

Signature:	Lung H	1999 Kuo	Date:	2014/08/22
	Lung-Huang Kuo			······

	NT (o. 14/315,642 aket No. 65322-90892	1 (001910US)
Signature:	Hsiao-Ping Fan	Fang

Signature:	Hsiao-Ping Fan	Date:	<u> 2014/08/26</u>
Signature:	Ming-Feng Wu Ming-Feng Wu	Date:	2014/08/22
Signature:	Yn-Sheng Chang	Date:	2014/08/22

Assignee hereby accepts this Assignment:

Name: Yung-Fa Chen, Ph.D.

Title: President and CEO

66507102V.1

PATENT REEL: 033646 FRAME: 0238

RECORDED: 09/01/2014